Efficacy and Safety of Paliperidone Extended-Release Tablets: Results of a 6-Week, Randomized, Placebo-Controlled Study

Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning.

2000 • 1,090 citations

Relationship Between Dopamine D₂ Occupancy, Clinical Response, and Side Effects: A Double-Blind PET Study of First-Episode Schizophrenia

2000 • 1,036 citations

The Effects of Risperidone on the Five Dimensions of Schizophrenia Derived by Factor Analysis

1997 • 705 citations

Association of Diabetes Mellitus With Use of Atypical Neuroleptics in the Treatment of Schizophrenia

2002 • 635 citations

Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social funtioning

2000 • 559 citations

Risperidone in the Treatment of Patients with Chronic Schizophrenia: a Multi-National, Multi-Centre, Double-Blind, Parallel-Group Study versus Haloperidol

1995 • 558 citations

Consensus Statement: Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes

2004 • 371 citations

Treatment of schizophrenia with paliperidone extended-release tablets: A 6-week placebo-controlled trial☆

2006 • 282 citations

Evaluation of Drug-Induced QT Interval Prolongation

2001 • 273 citations

Paliperidone Extended-Release Tablets for Prevention of Symptom Recurrence in Patients With Schizophrenia

2007 • 205 citations

Olanzapine

2001 • 202 citations

Partial Compliance and Patient Consequences in Schizophrenia

2003 • 202 citations

Clinical spectrum of the osmotic-controlled release oral delivery system (OROS), an advanced oral delivery form

2006 • 180 citations

Dropout rates in randomised antipsychotic drug trials

2001 • 167 citations

Clinical Global Impressions Scale

1976 • 167 citations

Subjective well-being and quality of life under atypical antipsychotic treatment

2002 • 140 citations

Comparison of the effects of different routes of antipsychotic administration on pharmacokinetics and pharmacodynamics.

2003 • 118 citations

Defining and Measuring Clinical Effectiveness in the Treatment of Schizophrenia

2005 • 117 citations

Efficacy and safety of risperidone in the long-term treatment of patients with schizophrenia

1995 • 104 citations

Double-blind Comparison of Risperidone and Haloperidol in Schizophrenic and Schizoaffective Psychoses

1993 • 99 citations

Social functioning and quality of life in the schizophrenic patient: advantages of amisulpride

2002 • 75 citations

Untitled

1997 • 74 citations

The increase in risk of diabetes mellitus from exposure to second-generation antipsychotic agents

2004 • 58 citations

Long-term treatment of chronic schizophrenia with risperidone

1998 • 46 citations

Switching Antipsychotic Therapies

2000 • 42 citations

Moderators of placebo response to antipsychotic treatment in patients with schizophrenia: a meta-regression

2003 • 40 citations

PIII-57Pharmacokinetics and dopamine D2 And serotonin 5-HT2A receptor occupancy of paliperidone in healthy subjects: Two open-label, single-dose studies

2006 • 37 citations

Schizophrenia: Do we really need placebo-controlled studies?

1998 • 20 citations

Absorption; metabolism and excretion of a single oral dose of 14c-paliperidone 1mg in healthy subjects (PAL-053)

2007 • 18 citations

Importance of individual anatomical variability in repetitive transcranial magnetic stimulation research.

2005 • 2 citations

Cited By (0)

Loading...